Avenzo Therapeutics
SAN DIEGO, CA · Biotechnology, Pharmaceutical, Therapeutics · 2 employees
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients. The company’s lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors.
Funding history
- Venture - Series Unknown — $47.2M — Sep 2025
- Venture - Series Unknown — $385.9M — Nov 2024
- Venture - Series Unknown — $223.4M — Mar 2024
- Series A — $150.0M — Mar 2024
- Pre-Seed — $243K — Feb 2023
Recent signals
- Nov 20, 2025: Avenzo Therapeutics Appoints Scott Lipman as Chief Financial Officer
- Sep 05, 2025: Raised $47.2M in Venture - Series Unknown
- Nov 20, 2024: Raised $385.9M in Venture - Series Unknown
- Sep 03, 2024: Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences for HR+/HER2- Metastatic Breast Cancer
- Mar 26, 2024: Raised $223.4M in Venture - Series Unknown
- Mar 26, 2024: Raised $150.0M in Series A
- Feb 14, 2023: Raised $243K in Pre-Seed
- Nov 08, 2022: Acquired Avenue Therapeutics Completes The Acquisition Of Baergic Bio And Its Selective Gaba-A Α2/3 Receptor Positive Allosteric Modulator For The Treatment Of Central Nervous System Disorders
See plans & pricing → Track Avenzo Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.